As a pioneering RNA therapeutics company (HKEX: 2257), we are redefining the boundaries of RNA interference with breakthrough delivery platforms, turning scientific promise into healing for patients worldwide.

Our proprietary PNP (Peptide Nanoparticle) platform overcomes the critical challenge of extra-hepatic RNAi delivery, unlocking new frontiers from oncology to regenerative and aesthetic medicine.

With our GalAHead™ technology, we achieve precise, programmable control over therapeutic duration—enabling new paradigms for cardiovascular and metabolic diseases where sustained, long-term silencing is the key to success.

We are more than a drug developer; we are custodians of possibility. We carry the urgency of unmet medical needs with scientific rigor, pushing the boundaries of RNAi to deliver not just treatments, but enduring hope.